Merus N.V. (MRUS) Financial Ratios
12 years of historical data (2013–2024) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: N/A
P/B Ratio
↓
8.92
↑+125% vs avg
5yr avg: 3.97
30Y Low2.6·High7.8
ROE
↑
-41.4%
↓+6% vs avg
5yr avg: -43.9%
30Y Low-175%·High-28%
Debt/EBITDA
N/A
—
5yr avg: N/A
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
MRUS Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Merus N.V. currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $6.8B | $2.7B | $1.4B | $695M | $1.2B | $513M | $341M | $312M | $372M | $279M | — |
| Enterprise Value | $6.5B | $2.4B | $1.2B | $561M | $991M | $354M | $149M | $148M | $193M | $220M | — |
| P/E Ratio → | -26.87 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 195.71 | 77.42 | 35.65 | 17.89 | 28.48 | 20.92 | 12.29 | 9.31 | 16.99 | 111.26 | — |
| P/B Ratio | 8.92 | 4.17 | 3.98 | 2.81 | 3.89 | 5.02 | 2.60 | 2.97 | 6.48 | 7.80 | — |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
MRUS EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 69.30 | 30.81 | 14.44 | 22.97 | 14.43 | 5.36 | 4.41 | 8.80 | 87.62 | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — | — |
MRUS Profitability
Margins and return-on-capital ratios measuring operating efficiency
Merus N.V. earns an operating margin of -753.0%. Operating margins have compressed from -384.8% to -753.0% over the past 3 years, signaling potential cost pressures or competitive headwinds. A negative ROE of -41.4% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 37.2% | 37.2% | 73.6% | 74.4% | -99.9% | -133.9% | -78.8% | -42.7% | -55.7% | -634.0% | -749.4% |
| Operating Margin | -753.0% | -753.0% | -356.2% | -384.8% | -183.2% | -253.4% | -188.4% | -119.2% | -161.1% | -1110.8% | -1213.2% |
| Net Profit Margin | -595.9% | -595.9% | -352.6% | -315.5% | -136.1% | -285.6% | -177.1% | -73.8% | -295.6% | -1889.9% | -1220.8% |
Return on Capital
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -41.4% | -41.4% | -46.5% | -43.5% | -28.1% | -59.9% | -41.6% | -30.4% | -138.9% | -142.2% | -174.8% |
| ROA | -33.5% | -33.5% | -33.7% | -29.4% | -17.1% | -28.3% | -19.2% | -10.2% | -41.5% | -82.6% | -107.9% |
| ROIC | -74.6% | -74.6% | -77.0% | -117.2% | -547.7% | — | — | — | — | — | — |
| ROCE | -48.4% | -48.4% | -41.5% | -43.8% | -27.8% | -30.2% | -23.6% | -18.6% | -25.1% | -55.9% | -158.8% |
MRUS Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $293M exceeds total debt of $10M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.02 | 0.02 | 0.03 | 0.05 | 0.01 | 0.04 | 0.04 | — | — | 0.01 | 0.02 |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.44 | -0.54 | -0.54 | -0.75 | -1.56 | -1.47 | -1.56 | -3.13 | -1.66 | -1.14 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | — | -612.81 | — | — | — | -154.87 | — | -108.40 |
Net cash position: cash ($293M) exceeds total debt ($10M)
MRUS Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
Merus N.V.'s current ratio of 6.54x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has improved from 3.88x to 6.54x over the past 3 years.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 6.54 | 6.54 | 5.34 | 3.88 | 5.90 | 4.66 | 6.72 | 6.75 | 10.05 | 9.17 | 5.46 |
| Quick Ratio | 6.54 | 6.54 | 5.34 | 3.88 | 5.90 | 4.66 | 6.72 | 6.75 | 10.05 | 7.64 | 5.46 |
| Cash Ratio | 6.17 | 6.17 | 5.14 | 3.68 | 5.71 | 4.44 | 6.52 | 6.51 | 9.81 | 7.34 | 5.20 |
| Asset Turnover | — | 0.04 | 0.09 | 0.10 | 0.09 | 0.11 | 0.11 | 0.13 | 0.09 | 0.03 | 0.05 |
| Inventory Turnover | 1.48 | — | — | — | — | — | — | — | — | 1.48 | — |
| Days Sales Outstanding | — | 49.29 | 36.50 | 44.15 | 56.45 | 26.04 | 34.88 | 52.92 | 62.90 | 179.39 | 2.09 |
MRUS Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Merus N.V. does not currently pay a dividend and has no material buyback yield, reinvesting earnings back into the business.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — |
| Shares Outstanding | — | $64M | $52M | $45M | $39M | $29M | $24M | $22M | $19M | $13M | $15M |
Peer Comparison
Compare MRUS with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 MRUSYou | $7B | -26.9 | — | — | 37.2% | -753.0% | -41.4% | -74.6% | — |
 ZYME | $2B | -25.6 | 0.3 | — | 89.8% | -87.3% | -26.7% | -25.9% | 0.0 |
 IMVT | $6B | -10.5 | — | — | — | — | -62.5% | — | — |
 AGEN | $137M | -1144.1 | — | — | 90.3% | -18.0% | — | — | — |
 FATE | $264M | -2.0 | — | — | — | -2222.4% | -51.8% | -36.5% | — |
 XNCR | $954M | -10.5 | — | — | 91.6% | -141.4% | -14.0% | -16.3% | — |
 REGN | $75B | 17.4 | 18.1 | 18.4 | 85.4% | 24.9% | 14.9% | 8.9% | 0.7 |
 ABBV | $363B | 86.5 | 15.1 | 20.4 | 70.2% | 32.8% | 6214.7% | 23.9% | 2.4 |
 RGEN | $7B | 146.2 | 52.2 | 75.5 | 47.1% | 8.1% | 2.4% | 2.2% | 5.0 |
 ALNY | $40B | 130.0 | 71.9 | 86.9 | 81.8% | 13.5% | 73.3% | 33.4% | 2.3 |
 INCY | $20B | 15.6 | 11.8 | 14.7 | 91.5% | 26.1% | 29.9% | 51.1% | 0.0 |
| Healthcare Median | — | 22.1 | 14.1 | 18.7 | 63.9% | -5.3% | -33.7% | -10.8% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 12 years · Updated daily
See MRUS's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs MRUS Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare MRUS vs ZYME
Side-by-side business, growth, and profitability comparison vs Zymeworks Inc..
Start ComparisonMRUS — Frequently Asked Questions
Quick answers to the most common questions about buying MRUS stock.
What is Merus N.V.'s P/E ratio?
Merus N.V.'s current P/E ratio is -26.9x. This places it at the 50th percentile of its historical range.
What is Merus N.V.'s ROE?
Merus N.V.'s return on equity (ROE) is -41.4%. The historical average is -76.4%.
Is MRUS stock overvalued?
Based on historical data, Merus N.V. is trading at a P/E of -26.9x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are Merus N.V.'s profit margins?
Merus N.V. has 37.2% gross margin and -753.0% operating margin.